TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Informing Decisions in Chronic Critical Illness: A Randomized Control Trial (RCT)
Brief Summary: The purpose of this study is to test a communication intervention to support family decision-making for patients with chronic critical illness.


Options:
A: Arm Label: Supportive Information Team Group; Type: EXPERIMENTAL; Interventions: Behavioral: Supportive Information Team Group | Arm Label: Usual Care Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Supportive Information Team Group; Assigned to Arm(s): Supportive Information Team Group
B: Arm Label: Arm I: Geriatric Assessment Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Geriatric Assessment Summary, Behavioral: Geriatric Assessment Targeted Recommendations, Behavioral: Geriatric Assessment (GA) | Arm Label: Arm II: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Geriatric Assessment (GA) | Intervention Type: BEHAVIORAL; Name: Geriatric Assessment Summary; Assigned to Arm(s): Arm I: Geriatric Assessment Intervention | Intervention Type: BEHAVIORAL; Name: Geriatric Assessment Targeted Recommendations; Assigned to Arm(s): Arm I: Geriatric Assessment Intervention | Intervention Type: BEHAVIORAL; Name: Geriatric Assessment (GA); Assigned to Arm(s): Arm I: Geriatric Assessment Intervention, Arm II: Usual Care
C: Arm Label: Routine data collection; Type: ACTIVE_COMPARATOR; Interventions: Other: Routine Data collection | Arm Label: Feedback of patient-reported outcomes; Type: EXPERIMENTAL; Interventions: Other: Routine Data collection, Other: Feedback of patient-reported outcomes | Intervention Type: OTHER; Name: Routine Data collection; Assigned to Arm(s): Feedback of patient-reported outcomes, Routine data collection | Intervention Type: OTHER; Name: Feedback of patient-reported outcomes; Assigned to Arm(s): Feedback of patient-reported outcomes
D: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Control | Arm Label: Verbal Information and Discussion; Type: EXPERIMENTAL; Interventions: Other: Verbal Information and Discussion | Intervention Type: OTHER; Name: Verbal Information and Discussion; Assigned to Arm(s): Verbal Information and Discussion | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Intensive Blood Pressure Control on Progression of Coronary Atherosclerosis: Randomized Evaluation by Intravascular Ultrasound
Brief Summary: The purpose of this study is to evaluate the effect of intensive blood pressure control compared to standard blood pressure control on progression of coronary atherosclerosis by intravascular ultrasound in hypertensive patients with coronary artery disease.


Options:
A: Arm Label: intensive blood pressure control; Type: ACTIVE_COMPARATOR; Interventions: Drug: control systolic blood pressure less than 120 mmHg | Arm Label: standard blood pressure control; Type: ACTIVE_COMPARATOR; Interventions: Drug: control systolic blood pressure less than 140 mmHg | Intervention Type: DRUG; Name: control systolic blood pressure less than 120 mmHg; Assigned to Arm(s): intensive blood pressure control | Intervention Type: DRUG; Name: control systolic blood pressure less than 140 mmHg; Assigned to Arm(s): standard blood pressure control
B: Arm Label: Intensive Control of SBP; Type: EXPERIMENTAL; Interventions: Drug: Intensive control of SBP | Arm Label: Standard Control of SBP; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard control of SBP | Intervention Type: DRUG; Name: Intensive control of SBP; Assigned to Arm(s): Intensive Control of SBP | Intervention Type: DRUG; Name: Standard control of SBP; Assigned to Arm(s): Standard Control of SBP
C: Arm Label: Initial presentation of coronary disease - Stable angina; Type: N/A; Interventions: N/A | Arm Label: Initial presentation of coronary disease - ACS; Type: N/A; Interventions: N/A | Arm Label: Initial presentation of coronary disease - Coronary death; Type: N/A; Interventions: N/A | Arm Label: Initial presentation of coronary disease - None; Type: N/A; Interventions: N/A
D: Arm Label: Intensive; Type: EXPERIMENTAL; Interventions: Other: Anti-hypertensive therapy to SBP 130 mm Hg | Arm Label: Standard; Type: ACTIVE_COMPARATOR; Interventions: Other: Anti-hypertensive therapy to SBP 145 mm Hg | Intervention Type: OTHER; Name: Anti-hypertensive therapy to SBP 130 mm Hg; Assigned to Arm(s): Intensive | Intervention Type: OTHER; Name: Anti-hypertensive therapy to SBP 145 mm Hg; Assigned to Arm(s): Standard

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Intensive Blood Pressure Control on Progression of Coronary Atherosclerosis: Randomized Evaluation by Intravascular Ultrasound
Brief Summary: The purpose of this study is to evaluate the effect of intensive blood pressure control compared to standard blood pressure control on progression of coronary atherosclerosis by intravascular ultrasound in hypertensive patients with coronary artery disease.


Options:
A: Arm Label: The intensive care group; Type: EXPERIMENTAL; Interventions: Drug: Amlodipine 5mg, Drug: Losartan, Drug: Losartan and Amlodipine, Drug: Amlodipine/Losartan/Chlorthalidone | Arm Label: The usual care group; Type: EXPERIMENTAL; Interventions: Drug: Amlodipine 5mg, Drug: Losartan, Drug: Losartan and Amlodipine, Drug: Amlodipine/Losartan/Chlorthalidone, Drug: current treatment | Intervention Type: DRUG; Name: Amlodipine 5mg; Assigned to Arm(s): The intensive care group, The usual care group | Intervention Type: DRUG; Name: Losartan; Assigned to Arm(s): The intensive care group, The usual care group | Intervention Type: DRUG; Name: Losartan and Amlodipine; Assigned to Arm(s): The intensive care group, The usual care group | Intervention Type: DRUG; Name: Amlodipine/Losartan/Chlorthalidone; Assigned to Arm(s): The intensive care group, The usual care group | Intervention Type: DRUG; Name: current treatment; Assigned to Arm(s): The usual care group
B: Arm Label: intensive blood pressure control; Type: ACTIVE_COMPARATOR; Interventions: Drug: control systolic blood pressure less than 120 mmHg | Arm Label: standard blood pressure control; Type: ACTIVE_COMPARATOR; Interventions: Drug: control systolic blood pressure less than 140 mmHg | Intervention Type: DRUG; Name: control systolic blood pressure less than 120 mmHg; Assigned to Arm(s): intensive blood pressure control | Intervention Type: DRUG; Name: control systolic blood pressure less than 140 mmHg; Assigned to Arm(s): standard blood pressure control
C: Arm Label: Intensive Control of SBP; Type: EXPERIMENTAL; Interventions: Drug: Intensive control of SBP | Arm Label: Standard Control of SBP; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard control of SBP | Intervention Type: DRUG; Name: Intensive control of SBP; Assigned to Arm(s): Intensive Control of SBP | Intervention Type: DRUG; Name: Standard control of SBP; Assigned to Arm(s): Standard Control of SBP
D: Arm Label: Intensive; Type: EXPERIMENTAL; Interventions: Other: Anti-hypertensive therapy to SBP 130 mm Hg | Arm Label: Standard; Type: ACTIVE_COMPARATOR; Interventions: Other: Anti-hypertensive therapy to SBP 145 mm Hg | Intervention Type: OTHER; Name: Anti-hypertensive therapy to SBP 130 mm Hg; Assigned to Arm(s): Intensive | Intervention Type: OTHER; Name: Anti-hypertensive therapy to SBP 145 mm Hg; Assigned to Arm(s): Standard

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Feasibility of Comparing Two Surgical Treatment of Female Urodynamic Stress Incontinence (SITOT)
Brief Summary: Aim: The study aim to assess the feasibly a large prospective multi-centre randomised study for comparing the relatively new "Single incision sub-urethral tapes" with the standard surgical treatment of female urodynamic stress incontinence (USI).


Options:
A: Arm Label: Single-incision Mini-slings (SIMS- Ajust); Type: EXPERIMENTAL; Interventions: Procedure: sub-urethral tape (TVT-O) | Arm Label: standared med urethral sling (SMUS); Type: OTHER; Interventions: Other: stand standard mid-urethral sling (TVT-O) | Intervention Type: PROCEDURE; Name: sub-urethral tape (TVT-O); Assigned to Arm(s): Single-incision Mini-slings (SIMS- Ajust) | Intervention Type: OTHER; Name: stand standard mid-urethral sling (TVT-O); Assigned to Arm(s): standared med urethral sling (SMUS)
B: Arm Label: TVT-O; Type: ACTIVE_COMPARATOR; Interventions: Device: TVT-O | Arm Label: TVT-S; Type: ACTIVE_COMPARATOR; Interventions: Device: TVT-S | Intervention Type: DEVICE; Name: TVT-O; Assigned to Arm(s): TVT-O | Intervention Type: DEVICE; Name: TVT-S; Assigned to Arm(s): TVT-S
C: Arm Label: Ajust; Type: EXPERIMENTAL; Interventions: Device: Ajust sling | Arm Label: Classical transobturator tape; Type: ACTIVE_COMPARATOR; Interventions: Device: Classical transobturator sling | Intervention Type: DEVICE; Name: Ajust sling; Assigned to Arm(s): Ajust | Intervention Type: DEVICE; Name: Classical transobturator sling; Assigned to Arm(s): Classical transobturator tape
D: Arm Label: TVT SECURE; Type: ACTIVE_COMPARATOR; Interventions: Procedure: transvaginal obturator tape | Arm Label: TVT O; Type: ACTIVE_COMPARATOR; Interventions: Procedure: transvaginal obturator tape | Intervention Type: PROCEDURE; Name: transvaginal obturator tape; Assigned to Arm(s): TVT O, TVT SECURE

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Double-Blind, Randomized-Withdrawal Trial of Subcutaneous Golimumab, a Humanized Anti-TNFa Antibody, in Subjects With Active Polyarticular Juvenile Idiopathic Arthritis (JIA) Despite Standard Therapy
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of golimumab (CNTO 148) in patients who have active juvenile idiopathic arthritis (JIA) and at least 5 joints with active arthritis that have poor response to methotrexate.


Options:
A: Arm Label: adalimumab; Type: EXPERIMENTAL; Interventions: Drug: Anti-tumor necrosis factor alpha monoclonal antibody | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Anti-tumor necrosis factor alpha monoclonal antibody; Assigned to Arm(s): adalimumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
B: Arm Label: Continue adalimumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab | Arm Label: Stop adalimumab; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Continue adalimumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Stop adalimumab
C: Arm Label: CNTO 148 (Golimumab); Type: EXPERIMENTAL; Interventions: Drug: CNTO 148 (Golimumab), Drug: Methotrexate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Methotrexate | Intervention Type: DRUG; Name: CNTO 148 (Golimumab); Assigned to Arm(s): CNTO 148 (Golimumab) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): CNTO 148 (Golimumab), Placebo
D: Arm Label: Infliximab plus Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Infliximab plus methotrexate | Arm Label: Combination of DMARDs; Type: EXPERIMENTAL; Interventions: Drug: Combination of DMARDs | Arm Label: Methotrexate alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate alone | Intervention Type: DRUG; Name: Infliximab plus methotrexate; Assigned to Arm(s): Infliximab plus Methotrexate | Intervention Type: DRUG; Name: Combination of DMARDs; Assigned to Arm(s): Combination of DMARDs | Intervention Type: DRUG; Name: Methotrexate alone; Assigned to Arm(s): Methotrexate alone

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Trial of AMG 479 or Placebo in Combination With Gemcitabine as First Line Therapy for Metastatic Adenocarcinoma of the Pancreas
Brief Summary: AMG 479 is an investigational fully human monoclonal antibody that targets type 1 insulin-like growth factor receptor (IGF-1R). Signaling through IGF-1R plays an important role in the regulation of cell growth and survival. The primary purpose of the study is to determine if AMG 479 and gemcitabine improves overall survival as compared to placebo and gemcitabine.


Options:
A: Arm Label: A; Type: NO_INTERVENTION; Interventions: Genetic: cetuximab | Intervention Type: GENETIC; Name: cetuximab; Assigned to Arm(s): A
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: docetaxel, Drug: fluorouracil, Radiation: radiation therapy | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: cisplatin, Drug: docetaxel, Radiation: radiation therapy | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: DRUG; Name: fluorouracil; Assigned to Arm(s): Arm 1 | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Arm 1, Arm 2
C: Arm Label: Placebo + gemcitabine; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: gemcitabine | Arm Label: AMG 479 12 mg/kg dose + gemcitabine; Type: EXPERIMENTAL; Interventions: Drug: AMG 479, Drug: gemcitabine | Arm Label: AMG 479 20 mg/kg + gemcitabine; Type: EXPERIMENTAL; Interventions: Drug: AMG 479, Drug: gemcitabine | Intervention Type: DRUG; Name: AMG 479; Assigned to Arm(s): AMG 479 12 mg/kg dose + gemcitabine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + gemcitabine | Intervention Type: DRUG; Name: AMG 479; Assigned to Arm(s): AMG 479 20 mg/kg + gemcitabine | Intervention Type: DRUG; Name: gemcitabine; Assigned to Arm(s): AMG 479 12 mg/kg dose + gemcitabine, AMG 479 20 mg/kg + gemcitabine, Placebo + gemcitabine
D: Arm Label: 5-FU & LV; Type: ACTIVE_COMPARATOR; Interventions: Drug: Leucovorin, Drug: 5-Fluorouracil | Arm Label: XELOX or modified FOLFOX-6; Type: EXPERIMENTAL; Interventions: Drug: Leucovorin, Drug: OXALIPLATIN, Drug: 5-Fluorouracil | Intervention Type: DRUG; Name: Leucovorin; Assigned to Arm(s): 5-FU & LV, XELOX or modified FOLFOX-6 | Intervention Type: DRUG; Name: OXALIPLATIN; Assigned to Arm(s): XELOX or modified FOLFOX-6 | Intervention Type: DRUG; Name: 5-Fluorouracil; Assigned to Arm(s): 5-FU & LV, XELOX or modified FOLFOX-6

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open, Randomized, Crossover Phase 2 Pilot Study of Treatment of Stage 3B Renal Failure With Active Vitamin D or a Phosphate Binder to Evaluate the Effect on the FGF23 and PTH Levels.
Brief Summary: Patients with reduced renal function normally develop hyperparathyroidism, which in turn is associated with increased cardiovascular risk and de-calcification. Hyperparathyroidism may be enhanced by an increased level of FGF23 which is often seen in the early stage of renal failure. This pilot study will investigate the FGF23-lowering effect of early initiation of treatment with a phosphate binder versus active vitamin D in an open crossover design.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sevelamer carbonate | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sevelamer carbonate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: Renvela; Type: EXPERIMENTAL; Interventions: Drug: Renvela | Arm Label: Etalpha; Type: EXPERIMENTAL; Interventions: Drug: Etalpha | Intervention Type: DRUG; Name: Renvela; Assigned to Arm(s): Renvela | Intervention Type: DRUG; Name: Etalpha; Assigned to Arm(s): Etalpha
C: Arm Label: PA21; Type: EXPERIMENTAL; Interventions: Drug: PA21 (2.5 g tablet containing 500 mg iron) | Arm Label: Sevelamer carbonate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sevelamer carbonate | Intervention Type: DRUG; Name: PA21 (2.5 g tablet containing 500 mg iron); Assigned to Arm(s): PA21 | Intervention Type: DRUG; Name: Sevelamer carbonate; Assigned to Arm(s): Sevelamer carbonate
D: Arm Label: Sevelamer HCl; Type: EXPERIMENTAL; Interventions: Drug: Sevelamer HCl | Arm Label: Calcium-based binder; Type: ACTIVE_COMPARATOR; Interventions: Drug: Calcium-based phosphate binder | Intervention Type: DRUG; Name: Sevelamer HCl; Assigned to Arm(s): Sevelamer HCl | Intervention Type: DRUG; Name: Calcium-based phosphate binder; Assigned to Arm(s): Calcium-based binder

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Extended Letrozole Regimen Versus Clomiphene Citrate for Superovulation in Patients With Unexplained Infertility Undergoing Intrauterine Insemination
Brief Summary: The aim of this randomized controlled trial is to compare the efficacy of extended letrozole regimen (2.5mg/day from cycle day 1 to 9) with clomiphene citrate (100 mg/day from cycle day 3 to 7) in women with unexplained infertility undergoing superovulation and intrauterine insemination .


Options:
A: Arm Label: HP-hMG; Type: ACTIVE_COMPARATOR; Interventions: Drug: Meropur 150 a day | Arm Label: rFSH plus rLH; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gonal-f 150 plus Luveris 150 | Intervention Type: DRUG; Name: Meropur 150 a day; Assigned to Arm(s): HP-hMG | Intervention Type: DRUG; Name: Gonal-f 150 plus Luveris 150; Assigned to Arm(s): rFSH plus rLH
B: Arm Label: Aromatase Inhibitors (AI); Type: ACTIVE_COMPARATOR; Interventions: Drug: Letrozole (aromatase inhibitor) | Arm Label: Clomiphene Citrate (CC); Type: ACTIVE_COMPARATOR; Interventions: Drug: Clomiphene Citrate | Arm Label: Follicle Stimulating Hormone (FSH); Type: ACTIVE_COMPARATOR; Interventions: Drug: Follicle Stimulating Hormone (gonadotropin) | Intervention Type: DRUG; Name: Letrozole (aromatase inhibitor); Assigned to Arm(s): Aromatase Inhibitors (AI) | Intervention Type: DRUG; Name: Clomiphene Citrate; Assigned to Arm(s): Clomiphene Citrate (CC) | Intervention Type: DRUG; Name: Follicle Stimulating Hormone (gonadotropin); Assigned to Arm(s): Follicle Stimulating Hormone (FSH)
C: Arm Label: Extended letrozole regimen; Type: EXPERIMENTAL; Interventions: Drug: Extended letrozole regimen | Arm Label: Clomiphene citrate regimen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clomiphene citrate regimen | Intervention Type: DRUG; Name: Extended letrozole regimen; Assigned to Arm(s): Extended letrozole regimen | Intervention Type: DRUG; Name: Clomiphene citrate regimen; Assigned to Arm(s): Clomiphene citrate regimen
D: Arm Label: Tablets; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clomifen, Ethinyl Estradiol | Arm Label: human menopausal gonadotropins; Type: ACTIVE_COMPARATOR; Interventions: Drug: Menotropins | Intervention Type: DRUG; Name: Clomifen, Ethinyl Estradiol; Assigned to Arm(s): Tablets | Intervention Type: DRUG; Name: Menotropins; Assigned to Arm(s): human menopausal gonadotropins

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Antioxidant Supplementation in Pregnant Women With Low Antioxidant Status
Brief Summary: The purpose of this study is to investigate the benefit of several micro nutrients of antioxidants (using milk) in a cohort of women with low antioxidant status and the changes in cell-free mRNA.


Options:
A: Intervention Type: DRUG; Name: Nutritional supplements; Assigned to Arm(s): N/A
B: Arm Label: 5-methyltetrahydrofolate; Type: EXPERIMENTAL; Interventions: Dietary Supplement: 5-methyltetrahydrofolate | Arm Label: folic acid; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: folic Acid | Intervention Type: DIETARY_SUPPLEMENT; Name: 5-methyltetrahydrofolate; Assigned to Arm(s): 5-methyltetrahydrofolate | Intervention Type: DIETARY_SUPPLEMENT; Name: folic Acid; Assigned to Arm(s): folic acid
C: Arm Label: micronutrient antioxidant; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: micronutrient antioxidant | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Control | Intervention Type: DIETARY_SUPPLEMENT; Name: micronutrient antioxidant; Assigned to Arm(s): micronutrient antioxidant | Intervention Type: DIETARY_SUPPLEMENT; Name: Control; Assigned to Arm(s): Control
D: Arm Label: Multivitamins; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Multivitamins-vitamins B-complex, C, and E | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamins-vitamins B-complex, C, and E; Assigned to Arm(s): Multivitamins | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: I Change Adherence & Raise Expectations
Brief Summary: The iCARE study, a clustered-randomized controlled trial, is evaluating an adherence promotion intervention for adolescents that Cystic Fibrosis (CF) care teams will implement. Half the centers will receive the Comprehensive Adherence Program (CAP) for 2 years. CAP consists of training in the CF My Way program (a validated problem-solving adherence promotion intervention). The other half of the centers will receive CAP in year 2 of the study. Participants are patients age 11-20 years old who are diagnosed with CF and have been prescribed at least one of the following medications for at least 6 months prior to signing the informed consent: azithromycin, hypertonic saline, Pulmozyme®, TOBI®, or inhaled compounded tobramycin. Rate of refilling prescriptions is the primary outcome with lung function decline rates, exacerbation rates, and patient reported measures including health related quality of life and CF knowledge and skills, as secondary outcomes.

A central goal of this study is to test the effectiveness of the comprehensive adherence program (CAP), described above, versus standard care (SC) for adolescents and young adults seen in outpatient CF clinics.


Options:
A: Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Denufosol Tetrasodium (INS37217) Inhalation Solution | Intervention Type: DRUG; Name: Denufosol Tetrasodium (INS37217) Inhalation Solution; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: Comprehensive Adherence Program (CAP); Type: EXPERIMENTAL; Interventions: Behavioral: Comprehensive Adherence Program (CAP) | Arm Label: Standard Care (SC); Type: EXPERIMENTAL; Interventions: Behavioral: Comprehensive Adherence Program (CAP) | Intervention Type: BEHAVIORAL; Name: Comprehensive Adherence Program (CAP); Assigned to Arm(s): Comprehensive Adherence Program (CAP), Standard Care (SC)
C: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])
D: Intervention Type: DRUG; Name: hypertonic saline; Assigned to Arm(s): N/A

Answer: B